Aberrant MGMT (O6-methylguanine-DNA methyltransferase) promoter methylation in choroid plexus tumors

Journal of Neuro-Oncology

Volumn 91, Issue 2, 2009, Pages 151-155

  Hasselblatt, Martin ^a   Mühlisch, Jörg ^a   Wrede, Brigitte ^b   Kallinger, Birgit ^a   Jeibmann, Astrid ^a   Peters, Ove ^b   Kutluk, Tezer ^c   Wolff, Johannes E A ^d   Paulus, Werner ^a   Frühwald, Michael C ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c HACETTEPE UNIVERSITY   (Turkey)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Choroid plexus carcinoma; Choroid plexus papilloma; Methylation; Temozolomide

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;

ARTICLE; CHILD; CHOROID PLEXUS TUMOR; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; ENHANCER REGION; FEMALE; HUMAN; HUMAN TISSUE; MALE; POLYMERASE CHAIN REACTION; PROMOTER REGION; QUANTITATIVE ANALYSIS; RESTRICTION MAPPING; RETROSPECTIVE STUDY; SEQUENCE ANALYSIS;

ANTINEOPLASTIC AGENTS, ALKYLATING; CARCINOMA; CHILD, PRESCHOOL; CHOROID PLEXUS NEOPLASMS; CPG ISLANDS; DNA METHYLATION; FEMALE; HUMANS; INFANT; MALE; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PAPILLOMA; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA; SULFITES;

EID: 57449091307     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-008-9694-2     Document Type: Article

References (27)

1. Rickert CH, Paulus W (2001) Tumors of the choroid plexus. Microsc Res Tech 52:104-111. doi:10.1002/ 1097-0029(20010101)52:1<104::AID-JEMT12>3.0.CO;2-3
2. Jeibmann A, Hasselblatt M, Gerss J et al (2006) Prognostic implications of atypical histologic features in choroid plexus papilloma. J Neuropathol Exp Neurol 65:1069-1073. doi: 10.1097/ 01.jnen.0000240464.26005.90
3. Wrede B, Liu P, Wolff JE (2007) Chemotherapy improves the survival of patients with choroid plexus carcinoma: A meta-analysis of individual cases with choroid plexus tumors. J Neurooncol 85:345-351. doi: 10.1007/ s11060-007-9428-x
4. Wolff JE, Sajedi M, Coppes MJ et al (1999) Radiation therapy and survival in choroid plexus carcinoma. Lancet 353:2126. doi: 10.1016/ S0140-6736(99)01744-4
5. Broniscer A, Gururangan S, Macdonald TJ et al (2007) Phase I trial of single-dose temozolomide and continuous administration of O6-benzylguanine in children with brain tumors: A pediatric brain tumor consortium report. Clin Cancer Res 13:6712-6718. doi: 10.1158/ 1078-0432.CCR-07-1016
6. Lashford LS, Thiesse P, Jouvet A et al (2002) Temozolomide in malignant gliomas of childhood: A United Kingdom children's cancer study group and French society for pediatric oncology intergroup study. J Clin Oncol 20:4684-4691. doi: 10.1200/JCO.2002.08.141
7. Khaw SL, Coleman LT, Downie PA et al (2007) Temozolomide in pediatric low-grade glioma. Pediatr Blood Cancer 49:808-811. doi: 10.1002/pbc.21270
8. Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003. doi: 10.1056/NEJMoa043331
9. Donson AM, Addo-Yobo SO, Handler MH et al (2007) MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer 48:403-407. doi: 10.1002/pbc.20803
10. Jeuken JW, Cornelissen SJ, Vriezen M et al (2007) MS-MLPA: An attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest 87:1055-1065. doi: 10.1038/labinvest.3700664
11. Preusser M, Janzer RC, Felsberg J et al (2008) Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: Observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 18:520-532. doi: 10.1111/j.1750-3639.2008.00153.x
12. Tanaka S, Oka H, Fujii K et al (2005) Quantitation of O6-methylguanine-DNA methyltransferase gene messenger RNA in gliomas by means of real-time RT-PCR and clinical response to nitrosoureas. Cell Mol Neurobiol 25:1067-1071. doi: 10.1007/s10571-005-8475-0
13. Ehrich M, Nelson MR, Stanssens P et al (2005) Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci U S A 102:15785-15790. doi: 10.1073/pnas.0507816102
14. Michalowski MB, de Fraipont F, Michelland S et al (2006) Methylation of RASSF1A and TRAIL pathway-related genes is frequent in childhood intracranial ependymomas and benign choroid plexus papilloma. Cancer Genet Cytogenet 166:74-81. doi: 10.1016/j.cancergencyto.2005.09.004
15. McCall T, Binning M, Blumenthal DT et al (2006) Variations of disseminated choroid plexus papilloma: 2 case reports and a review of the literature. Surg Neurol 66:62-67. doi: 10.1016/j.surneu.2005.09.023
16. Wrede B, Peters O, Hasselblatt M et al (2007) An interim report of the International CPT-SIOP-2000. Pediatr Blood Cancer 49:426
17. Louis DN, Ohgaki H, Wiestler OD et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109. doi: 10.1007/s00401-007-0243-4
18. Hasselblatt M, Böhm C, Tatenhorst L et al (2006) Identification of novel diagnostic markers for choroid plexus tumors: A microarray-based approach. Am J Surg Pathol 30:66-74. doi: 10.1097/ 01.pas.0000176430.88702.e0
19. Judkins AR, Burger PC, Hamilton RL et al (2005) INI1 protein expression distinguishes atypical teratoid/rhabdoid tumor from choroid plexus carcinoma. J Neuropathol Exp Neurol 64:391-397
20. Danam RP, Qian XC, Howell SR et al (1999) Methylation of selected CpGs in the human O6-methylguanine-DNA methyltransferase promoter region as a marker of gene silencing. Mol Carcinog 24:85-89. doi:10.1002/ (SICI)1098-2744(199902)24:2<85::AID-MC2>3.0.CO;2-C
21. Herman JG, Graff JR, Myohanen S et al (1996) Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93:9821-9826. doi: 10.1073/pnas.93.18.9821
22. Mühlisch J, Schwering A, Grotzer M et al (2006) Epigenetic repression of RASSF1A but not CASP8 in supratentorial PNET (sPNET) and atypical teratoid/rhabdoid tumors (AT/RT) of childhood. Oncogene 25:1111-1117. doi: 10.1038/sj.onc.1209137
23. Frühwald MC, O'Dorisio MS, Dai Z et al (2001) Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas-implications for tumor biology and potential clinical utility. Oncogene 20:5033-5042. doi: 10.1038/ sj.onc.1204613
24. Qian XC, Brent TP (1997) Methylation hot spots in the 5′ flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene. Cancer Res 57:3672-3677
25. Mühlisch J, Bajanowski T, Rickert CH et al (2007) Frequent but borderline methylation of p16 (INK4a) and TIMP3 in medulloblastoma and sPNET revealed by quantitative analyses. J Neurooncol 83:17-29. doi: 10.1007/s11060-006-9309-8
26. Harris LC, Remack JS, Brent TP (1994) Identification of a 59 bp enhancer located at the first exon/intron boundary of the human O6-methylguanine DNA methyltransferase gene. Nucleic Acids Res 22:4614-4619. doi: 10.1093/nar/22.22.4614
27. Alonso ME, Bello MJ, Gonzalez-Gomez P et al (2004) Aberrant CpG island methylation of multiple genes in ependymal tumors. J Neurooncol 67:159-165. doi: 10.1023/B:NEON.0000021862.41799.f7